These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10669191)

  • 1. Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia.
    Wazny LD; Brophy DF
    Ann Pharmacother; 2000 Jan; 34(1):94-7. PubMed ID: 10669191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of amiloride on amphotericin B-induced hypokalaemia.
    Bearden DT; Muncey LA
    J Antimicrob Chemother; 2001 Jul; 48(1):109-11. PubMed ID: 11418519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Usefulness of Early Potassium Supplementation for Preventing Severe Hypokalemia Induced by Liposomal Amphotericin B in Hematologic Patients: A Retrospective Study.
    Okada N; Azuma M; Imanishi M; Zamami Y; Kirino Y; Nakamura T; Teraoka K; Abe M; Ishizawa K
    Clin Ther; 2018 Feb; 40(2):252-260. PubMed ID: 29305017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?
    Ural AU; Avcu F; Cetin T; Beyan C; Kaptan K; Nazaroglu NK; Yalcin A
    Eur J Clin Pharmacol; 2002 Jan; 57(11):771-3. PubMed ID: 11868798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diuretics and potassium/magnesium depletion. Directions for treatment.
    Ryan MP
    Am J Med; 1987 Mar; 82(3A):38-47. PubMed ID: 3551599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amiloride prevents amphotericin B related hypokalaemia in neutropenic patients.
    Smith SR; Galloway MJ; Reilly JT; Davies JM
    J Clin Pathol; 1988 May; 41(5):494-7. PubMed ID: 3290263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity.
    Karimzadeh I; Khalili H; Farsaei S; Dashti-Khavidaki S; Sagheb MM
    Eur J Clin Pharmacol; 2013 Jul; 69(7):1351-68. PubMed ID: 23361383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between potassium supplementation and the occurrence of acute kidney injury in patients with hypokalemia administered liposomal amphotericin B: a nationwide observational study.
    Ota Y; Obata Y; Takazono T; Tashiro M; Wakamura T; Takahashi A; Shiozawa Y; Miyazaki T; Nishino T; Izumikawa K
    BMC Nephrol; 2021 Jun; 22(1):240. PubMed ID: 34193064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis.
    Yamazaki H; Kondo T; Aoki K; Yamashita K; Takaori-Kondo A
    Diagn Microbiol Infect Dis; 2018 Feb; 90(2):123-131. PubMed ID: 29203252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Some aspects of diuretic therapy.
    Rowe WS
    Med J Aust; 1975 Mar; 1(12):392-4. PubMed ID: 1143129
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevention of thiazide-induced hypokalemia without magnesium depletion by potassium-magnesium-citrate.
    Odvina CV; Mason RP; Pak CY
    Am J Ther; 2006; 13(2):101-8. PubMed ID: 16645424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Hypokalemia as a Side Effect of Liposomal Amphotericin in Pediatric Patients.
    Kobayashi R; Keino D; Hori D; Sano H; Suzuki D; Kishimoto K; Kobayashi K
    Pediatr Infect Dis J; 2018 May; 37(5):447-450. PubMed ID: 28945677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuation of diuretic-induced hypokalemia by amiloride, a potassium-sparing agent.
    Ram CV; Holland OB; Kaplan NM
    J Clin Pharmacol; 1981; 21(11):484-7. PubMed ID: 7334141
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk factors of amphotericin B toxicty in the nonneonatal pediatric population.
    Dutta A; Palazzi DL
    Pediatr Infect Dis J; 2012 Sep; 31(9):910-4. PubMed ID: 22581225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Must we really fear toxicity of conventional amphotericin B in oncological patients?
    Mayer J; Doubek M; Vorlìcek J
    Support Care Cancer; 1999 Jan; 7(1):51-5. PubMed ID: 9926976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
    Wade RL; Chaudhari P; Natoli JL; Taylor RJ; Nathanson BH; Horn DL
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potassium depletion potentiates amphotericin-B-induced toxicity to renal tubules.
    Bernardo JF; Murakami S; Branch RA; Sabra R
    Nephron; 1995; 70(2):235-41. PubMed ID: 7566310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potassium/magnesium depletion in patients with cardiovascular disease.
    Dyckner T; Wester PO
    Am J Med; 1987 Mar; 82(3A):11-7. PubMed ID: 3565422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Potassium-sparing diuretics (spironolactone, triamterene, amylorid)].
    Haris A; Radó J
    Orv Hetil; 1996 Sep; 137(35):1907-14. PubMed ID: 8927344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potassium-sparing diuretics.
    Nurs Times; 2006 Jul 11-17; 102(28):31. PubMed ID: 16869220
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.